Citadel Advisors
KLRS

Citadel Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Citadel Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$390K Buy
+95,772
New +$497K ﹤0.01% 10497
2025
Q1 		– Sell
-6,674
Closed -$64.5K – 15893
2024
Q4 		$64.5K Buy
6,674
+3,013
+82% +$45.6K ﹤0.01% 12092
2024
Q3 		$68.1K Sell
3,661
-1,003
-22% -$17.5K ﹤0.01% 11595
2024
Q2 		$77.6K Sell
4,664
-1,693
-27% -$29.9K ﹤0.01% 11253
2024
Q1 		$110K Sell
6,357
-4,072
-39% -$66.4K ﹤0.01% 11216
2023
Q4 		$163K Buy
+10,429
New +$411K ﹤0.01% 10255
2023
Q3 		– Sell
-11,155
Closed -$760K – 15290
2023
Q2 		$872K Buy
11,155
+8,820
+378% +$838K ﹤0.01% 6745
2023
Q1 		$212K Sell
2,335
-1,047
-31% -$133K ﹤0.01% 10083
2022
Q4 		$399K Buy
+3,382
New +$574K ﹤0.01% 8722
2022
Q2 		– Sell
-4,737
Closed -$497K – 14323
2022
Q1 		$736K Buy
4,737
+2,123
+81% +$424K ﹤0.01% 8444
2021
Q4 		$778K Buy
+2,614
New +$1.21M ﹤0.01% 8566
2020
Q4 		– Sell
-1,674
Closed -$1.06M – 11640
2020
Q3 		$1.06M Buy
+1,674
New +$1.14M ﹤0.01% 5935

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's KLRS Position: Q2 2026 in Review

Citadel Advisors opened a new position in Kalaris Therapeutics (KLRS) in Q2 2026: 95,772 shares worth $390K. The stake represents ﹤0.01% of the portfolio and ranks #10497 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in KLRS as recently as Q4 2024.

Citadel Advisors first reported a position in KLRS in Q3 2020 and has held it in 12 quarters since. The position peaked at $1.06M in Q3 2020. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Citadel Advisors held 95,772 shares of Kalaris Therapeutics worth $390K as of Q2 2026.
  • Kalaris Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10497 holding.
  • Citadel Advisors first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 12 quarters since.
  • Citadel Advisors's Kalaris Therapeutics position peaked at $1.06M in Q3 2020.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.